NDAINTRAVENOUSPOWDERPriority Review
Approved
Feb 2004
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
21
Data completeness
4/8 — Partial
Priority Review
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ALIMTA (pemetrexed disodium) is a folate antagonist small-molecule chemotherapy that inhibits multiple folate-dependent enzymes critical for cell replication. It is approved for non-small cell lung cancer, malignant mesothelioma, ovarian cancer, and several other solid tumors. The drug works by blocking thymidylate synthase and other nucleotide synthesis pathways, preventing tumor cell division.
$2MPart D
LOE ApproachingDeclining
Approaching loss of exclusivity with modest Part D spending signals a mature product with reduced team expansion opportunities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (21)
Pemetrexed Disodium and Hsp90 Inhibitor AUY922 in Treating Patients With Previously Treated Stage IV Non-Small Cell Lung Cancer
Started Jan 2014
13 enrolled
Recurrent Non-small Cell Lung CancerSquamous Cell Lung CancerStage IV Non-small Cell Lung Cancer
TaxoteRe Plus Cisplatin Versus AlImta Plus Cisplatin in 1st Line Non-squamous Cell Type Lung Cancer
Started Jul 2011
148 enrolled
Carcinoma, Non Small Cell Lung
Pemetrexed Disodium/Observation in Treating Patients W/ Malignant Pleural Mesothelioma w/Out Progressive Disease After 1st Line Chemotherapy
Started Apr 2010
72 enrolled
Malignant Mesothelioma
Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer
Started Feb 2010
313 enrolled
Lung Cancer
A Study of Alimta/Cisplatin/Gefitinib for Asian Non-smoking Participants With Non Small Cell Lung Cancer
Started Nov 2009
236 enrolled
Non Small Cell Lung Cancer
Worked on ALIMTA at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.